104037-38-9 Usage
General Description
"RARECHEM AN KA 0422" is a specific label for a chemical compound that is sold by RARECHEM. Unfortunately, without more information, it's challenging to provide a specific summary of its properties and uses. This difficulty comes from the fact that RARECHEM, a producer of complex organic compounds, uses such alphanumeric labels (like AN KA 0422) for various chemical products. Therefore, searching for accurate and detailed information about the particular chemical can seem daunting. Therefore, if you're using this chemical, be sure to follow safety protocols, as all chemicals can present potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 104037-38-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,0,3 and 7 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 104037-38:
(8*1)+(7*0)+(6*4)+(5*0)+(4*3)+(3*7)+(2*3)+(1*8)=79
79 % 10 = 9
So 104037-38-9 is a valid CAS Registry Number.
104037-38-9Relevant articles and documents
-
Jones
, p. 4207 (1952)
-
NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
-
, (2014/09/29)
The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
